Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance

Fineline Cube Jan 16, 2026
Company Drug

Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies

Fineline Cube Jan 16, 2026
Company Medical Device

Broncus Medical Inc. Launches First Regulatory Clinical Study for Targeted Lung Denervation System

Fineline Cube Jul 10, 2023

China-based Broncus Medical Inc., (HKG: 2216), a provider of precision intervention solutions focused on lung...

Company Deals Digital

Hainan Boao Lecheng Partners with Medlive for Medical Tourism and Online Doctor Education

Fineline Cube Jul 10, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a strategic partnership...

Company Drug

HutchMed Ltd Initiates Phase I Clinical Study for SHP2 Inhibitor HMPL-415 in Solid Tumors

Fineline Cube Jul 10, 2023

China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of a Phase I...

Company

GenScript Biotech Expands cGMP Manufacturing for Gene and Cell Therapy in Zhenjiang Facility

Fineline Cube Jul 10, 2023

China-based GenScript Biotech Corporation (HKG: 1548) has announced the expansion of its current Good Manufacturing...

Policy / Regulatory

China’s NAFR Enhances Tax Benefits for Private Health Insurance Purchases

Fineline Cube Jul 7, 2023

The National Administration of Financial Regulation (NAFR) in China has issued a Notification indicating that...

Company Deals

Jacobio Pharma Secures RMB 150 Million Investment to Advance Pipeline Programs

Fineline Cube Jul 7, 2023

China-based Jacobio Pharma (HKG: 1167) has announced receiving RMB 150 million (USD 20.7 million) in...

Company Medical Device

Genesis MedTech Secures Chinese Market Approval for ArtiSential Laparoscopic Surgical Device

Fineline Cube Jul 7, 2023

Singapore-based Genesis MedTech has announced that it has received market approval in China for its...

Company Drug

Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval

Fineline Cube Jul 7, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study

Fineline Cube Jul 7, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...

Company Deals

C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development

Fineline Cube Jul 7, 2023

China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint...

Company Deals

ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion

Fineline Cube Jul 7, 2023

China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to...

Company Medical Device

Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China

Fineline Cube Jul 7, 2023

Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced...

Company Deals

Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007

Fineline Cube Jul 7, 2023

Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...

Company Deals

Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy

Fineline Cube Jul 6, 2023

Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced...

Policy / Regulatory

CDE Launches Trial Procedures for Adding Pediatric Information to Drug Inserts

Fineline Cube Jul 6, 2023

The Center for Drug Evaluation (CDE) has released the “Work Procedures for Adding Children’s Drug...

Company Deals

Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies

Fineline Cube Jul 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star...

Company Drug

3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus

Fineline Cube Jul 6, 2023

China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...

Company Deals

Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements

Fineline Cube Jul 6, 2023

China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Esflurbiprofen Patch Clinical Study

Fineline Cube Jul 6, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development

Fineline Cube Jul 6, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...

Posts pagination

1 … 450 451 452 … 610

Recent updates

  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
  • Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance
  • Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies
  • J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Company Drug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance

Company Drug

Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.